| Name | Title | Contact Details |
|---|
Unified Door & Hardware Group is a prominent distributor and service provider of commercial doors, hardware, and building specialties, located in Pennsauken, New Jersey. Established in 2013 from the merger of Commercial Hardware and TruFit, the company operates 31 locations nationwide and employs around 1,000 people, generating $92 million in revenue. In September 2024, it was acquired by Foundation Building Materials. The company offers a wide range of products and services across various construction divisions. This includes commercial doors and hardware, building specialties like bathroom partitions and fire protection, and access control systems. Unified Door & Hardware Group also provides custom fabrication, project management, professional engineering services, and installation for both new construction and aftermarket projects. They cater to diverse sectors such as healthcare, hospitality, government, and retail, working closely with contractors, developers, and building owners. Their extensive industry experience and commitment to personalized service set them apart in the market.
We are a committed team of engineers and market-makers who believe in the power of technology to deliver lasting change in tackling the colossal problem of microplastic pollution in our natural environment. The health of the worlds oceans and life on Earth depends on our contribution and the actions we take now as an organisation - there is no time to waste.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.